U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 31 - 40 of 183 results

NATALIZUMAB

MORE DETAILS

3JB47N2Q2P

Protein
Status:
US Approved Rx (2004)
First approved in 2004
Class:
PROTEIN

Cetuximab

MORE DETAILS

PQX0D8J21J

Protein
Status:
US Approved Rx (2004)
First approved in 2004
Class:
PROTEIN

ALEMTUZUMAB

MORE DETAILS

3A189DH42V

Protein
Status:
US Approved Rx (2001)
First approved in 2001
Class:
PROTEIN

GEMTUZUMAB OZOGAMICIN

MORE DETAILS

8GZG754X6M

Protein
Status:
US Approved Rx (2017)
First approved in 2000
Class:
PROTEIN

RITUXIMAB

MORE DETAILS

4F4X42SYQ6

Protein
Status:
US Approved Rx (2020)
First approved in 1997
Class:
PROTEIN

RAGIFILIMAB

MORE DETAILS

O440IW9NHN

Protein
Status:
Investigational
Class:
PROTEIN

TRASTUZUMAB DUOCARMAZINE

MORE DETAILS

XCR2BZ80N7

Protein
Status:
Investigational
Class:
PROTEIN

LORVOTUZUMAB MERTANSINE

MORE DETAILS

0IVD6ASY0W

Protein
Status:
Investigational
Class:
PROTEIN

CAMRELIZUMAB

MORE DETAILS

73096E137E

Protein
Status:
Investigational
Class:
PROTEIN

ECROMEXIMAB

MORE DETAILS

M76FX2JZRM

Protein
Status:
Investigational
Class:
PROTEIN
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966